Patent intelligence · US
US 11389566
Method and composition for treating inflammatory bowel disease
Method and composition for treating inflammatory bowel disease
Patent details — US 11389566
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 19, 2022
- Expiration
- Jul 14, 2042
- Applicant
- Regentys Corporation
- Claims
- 9
- CPC classes
- A61K, A61K35/22, A61K35/38, A61P
Quick answer
US 11389566 (Method and composition for treating inflammatory bowel disease) is held by Regentys Corporation. Status: granted. Granted Jul 19, 2022. Expires Jul 14, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regentys Corporation
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K35/22, A61K35/38, A61P, A61P1/00
More from Regentys Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11389566?
US 11389566 (Method and composition for treating inflammatory bowel disease) is held by Regentys Corporation. Status: granted. Granted Jul 19, 2022. Expires Jul 14, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11389566?
Regentys Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11389566 expire?
Our index shows an expiration date of Jul 14, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.